Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Mark Zafereo(Texas Medical Center), Maria Gule-Monroe(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Jennifer Wang(The University of Texas MD Anderson Cancer Center), Anastasios Maniakas(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center)
Cited by 72
Related Papers
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
|Journal of Clinical Oncology|2012|231
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid Carcinoma
|Thyroid|2019|229
Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses
|International Journal of Radiation Oncology*Biology*Physics|2016|149